MannKind reports PK/PD data supporting Furoscix ReadyFlow IV-equivalent exposure
MannKind said new PK/PD data presented at HFSA 2026 showed Furoscix ReadyFlow’s subcutaneous injection achieved IV-equivalent exposure and a diuretic effect.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.